Simply Wall St.
Is Regeneron (REGN) Still Attractively Priced After Mixed Recent Share Performance
š
AI Sentiment
Highly Positive
8/10
Regeneron Pharmaceuticals Inc. News
Latest updates and market news for REGN
16 news
Mar 1 - Mar 7, 2026
Page 1
24/7 Wall St.
Here Are Fridayās Top Wall Street Analyst Research Calls: BorgWarner, CoreWeave, Intuit, Marvell Technology, Netflix, Okta, Regeneron Pharmaceuticals, Trade Desk, and More
ā
AI Sentiment
Neutral
4/10
StockStory
1 Nasdaq 100 Stock to Consider Right Now and 2 We Brush Off
š
AI Sentiment
Negative
3/10
Simply Wall St.
Dupixent Approvals Expand Regeneronās Immunology Reach And Valuation Debate
š
AI Sentiment
Highly Positive
8/10
24/7 Wall St.
COWG Is Up While QQQ Slips. What the Free Cash Flow Screen Is Actually Doing
ā
AI Sentiment
Neutral
5/10
Insider Monkey
Jim Cramer Says āI Should Have Pulled the Trigger on Regeneronā
š
AI Sentiment
Positive
7/10
PR Newswire
Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight
š
AI Sentiment
Highly Positive
10/10
GlobeNewswire
7MM Asthma Market Insights, Epidemiology, and Market Forecast Report 2022-2036
š
AI Sentiment
Highly Positive
8/10
Insider Monkey
Sanofi (SNY) and Regeneronās Dupixent Recommended for EU Approval
š
AI Sentiment
Highly Positive
8/10
Zacks
REGN & SNY's Dupixent Gets CHMP Nod for Pediatric Use in Urticaria
š
AI Sentiment
Highly Positive
9/10
MT Newswires
RBC Raises Price Target on Regeneron Pharmaceuticals to $765 From $745, Keeps Sector Perform Rating
š
AI Sentiment
Positive
7/10
Simply Wall St.
Regeneronās Dupixent Win And Rare Disease Push Reshape Risk Reward Profile
š
AI Sentiment
Highly Positive
8/10
Share this news page